This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Kischkel S , Bergt S , Brock B , von Gronheim J , Herbst A , Epping MJ , Matheis G , Novosel E , Schneider J , Warnke P , Podbielski A , Roesner JP , Lelkes PI , Vollmar B
In Vivo Testing of Extracorporeal Membrane Ventilators: iLA-Activve Versus Prototype I-Lung
Asaio j. 2017 Mar/Apr;63(2) :185-192
PMID: 28092273 URL: https://www.ncbi.nlm.nih.gov/pubmed/28092273
AbstractA side-by-side comparison of the decarboxylation efficacy of two pump-driven venovenous extracorporeal lung assist devices, i.e., a first prototype of the new miniaturized ambulatory extracorporeal membrane ventilator, I-lung versus the commercial system iLA-activve for more than a period of 72 hours in a large animal model. Fifteen German Landrace pigs were anesthetized and underwent mechanical hypoventilation to induce severe hypercapnia. Decarboxylation was accomplished by either the I-lung or the iLA-activve via a double lumen catheter in the jugular vein. Sham-operated pigs were not connected to extracorporeal devices. Cardiovascular, respiratory, and metabolic parameters were continuously monitored, combined with periodic arterial blood sampling for subsequent clinical blood diagnostics, such as gas exchange, hemolysis, coagulation parameters, and cytokine profiles. At the termination of the studies, lung tissue was harvested and examined histologically for pulmonary morphology and leukocyte tissue infiltration. Both extracorporeal devices showed high and comparable efficacy with respect to carbon dioxide elimination for more than 72 hours and were not associated with either bleeding events or clotting disorders. Pigs of both groups showed cardiovascular and hemodynamic stability without marked differences to sham-operated animals. Groups also did not differ in terms of inflammatory and metabolic parameters. We established a preclinical in vivo porcine model for comparative long-term testing of I-lung and iLA-activve. The I-lung prototype proved to be safe and feasible, providing adequate decarboxylation without any adverse events. Once translated into the clinical treatment, the new miniaturized and transportable I-lung device might represent a promising tool for treating awake and mobilized patients with decompensated pulmonary disorders.
Notes1538-943x Kischkel, Sabine Bergt, Stefan Brock, Beate von Gronheim, Johan Herbst, Anne Epping, Marc-Jonas Matheis, Georg Novosel, Esther Schneider, Joerg Warnke, Philipp Podbielski, Andreas Roesner, Jan P Lelkes, Peter I Vollmar, Brigitte Comparative Study Journal Article United States ASAIO J. 2017 Mar/Apr;63(2):185-192. doi: 10.1097/MAT.0000000000000465.